anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: EXENATIDE
Trial phase: Not Applicable
ATC code: A10BJ01
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 11
Group description: Pre-dosed injectable pen (an automatic device which injects under the skin) 10 mcg twice a day of exenatide for 2.5 months

Exenatide: Subcutaneous injection 2.5 micrograms (mcg) to 10 mcg twice per day (BID)
Eligibility criteria:
Inclusion Criteria

Men and women between the ages of 45 and 70 years of age
Diagnosed with uncomplicated type 2 diabetes
Sedentary persons (exercising not more than one time per week)
Females who are post-menopausal
BMI must be less than 35
Subjects must be taking metformin for diabetes control and may also be on sulfonylurea drugs or meglitinides
Glycosylated hemoglobin (HbA1C) <9%
Non-smokers or former smokers who have quit for at least 1 year
Absence of comorbid conditions
Resting systolic blood pressure < 190, Resting diastolic blood pressure < 95

Exclusion Criteria

People with type 2 diabetes (T2D) taking oral medications, other than metformin or sulfonylurea drugs or meglitinides, to control their diabetes.
Persons treated with insulin will be excluded
People who are currently smoking or have not quit for at least one year
Peripheral neuropathy
Regional wall motion abnormalities
Left ventricular systolic dysfunction
Ischemic heart disease (abnormal resting or exercise electrocardiogram)
Presence of angina that would limit exercise performance
Pulmonary problems that would limit exercise performance
Systolic blood pressure >190 mmHg at rest or >250 mmHg with exercise or diastolic pressure >95 mmHg at rest or >115 mmHg with exercise
Persons with autonomic dysfunction (>20 mm fall in upright BP without a change in heart rate)
Proteinuria (urine protein >200 mg/dl) or a creatinine > 2.0 mg/dl
Renal disease
Persons with peripheral arterial disease
Persons with a history of pancreatitis
Intervention: Varenicline
Trial phase: Phase 2
ATC code: N07BA03 | S01XA28
SMILES: c1cnc2cc3c(cc2n1)C1CNCC3C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 27
Group description: Varenicline (Chantix (R))

Varenicline: Varenicline dosing will follow that which has been shown to be effective for cigarette smoking cessation. Varenicline dose will start at 0.5 mg daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 9).
Eligibility criteria:
Inclusion Criteria:

Contact site for additional information.

Exclusion Criteria:

Contact site for additional information.
Intervention: Pregabalin
Trial phase: Not Applicable
ATC code: N02BF02 | N03AX16
SMILES: CC(C)C[C@H](CN)CC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 86
Group description: Patients in the treatment group will receive 150 mg of pregabalin with a sip of water one hour prior to surgery, and then 150 mg daily (75 mg BID) for a total of two weeks.

Postoperative pain will be assessed daily until discharge using a verbal Numerical Rating Scale (NRS) at rest and during physical therapy, by both physical therapists and blinded research assistants.

All narcotics (i.v. PCA, oral or IM/SQ rescue doses) will be tabulated during their hospital stay, and patients will be asked to document their oral narcotic use after discharge.

On the day of discharge, patients will be given a self report data sheet, in which they will be asked to record their daily pain level at rest, with movement, and whether their pain interfered with sleep.

Pregabalin 150 mg: Patients will receive two 75 mg capsules of pregabalin 1 hour before surgery. They continue to take 2 capsules of 75 mg (total 150 mg) until POD 14.
Eligibility criteria:
Inclusion Criteria:

Patients for elective lumber posterior spinal fusions with segmental instrumentation

Exclusion Criteria:

Use of pregabalin or gabapentin within the washout period. Some chronic pain patients should not be subjected to a washout period for either medication prior to surgery, as determined by their pain management physician, and these patients will be excluded from the study.
Allergic sensitivity to pregabalin.
Renal insufficiency, Cr ≥ 1.5 mg/dl.
Active substance abuse.
Unstable mental condition.
Non English Speaking Patients.
Intervention: Cholecalciferol
Trial phase: Phase 2
ATC code: A11CC05 | A11CC55 | M05BB03 | M05BB04 | M05BB05 | M05BB07 | M05BB08 | M05BB09 | M05BX53
SMILES: [H][C@@]12CC[C@]([H])([C@H](C)CCCC(C)C)[C@@]1(C)CCC/C2=C\C=C1\C[C@@H](O)CCC1=C
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 20
Group description: 5000 IU Vitamin D3 to be given to the mother during pregnancy. 7000 IU Vitamin D3 to be given during breast feeding if breast feeding. If not breastfeeding, infant to be given 400 IU Vitamin D3 during first year of age, then increased to 1000 IU D3 until completion of research trial.

Vitamin D3: 5000 IU D3 capsule oral/day for entire pregnancy. 7000 IU D3/day during breastfeeding. If not breast feeding, baby gets 400 IU D3/day. Baby increased to 1000 IU D3/day at one year of age.
Eligibility criteria:
Inclusion Criteria:

Pregnant mothers who have had at least one child with autism spectrum disorder

Exclusion Criteria:

Child with autism must not be from a syndrome such as Fragile X syndrome, Retts Syndrome
Mother must be before the third trimester
Intervention: Ketamine
Trial phase: Not Applicable
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 38
Group description: Subjects were dosed with approximately 1.0 mg/kg, using ketamine as anesthetic prior to electroconvulsive therapy (ECT).
Eligibility criteria:
Inclusion criteria:

Diagnosis of depression, either unipolar or bipolar
Subjects receiving ECT at the Mayo Clinic

Exclusion criteria:

Subjects not giving their own consent to ECT
Subjects with schizophrenia, schizoaffective disorder, or dementia
Subjects diagnosed with a major neurological disorder such as epilepsy, Parkinson disease, multiple sclerosis, or a neurodegenerative dementia.
Intervention: Methohexital
Trial phase: Not Applicable
ATC code: N01AF01 | N05CA15 | N05CB01
SMILES: C=CCC1(C(C)C#CCC)C(=O)NC(=O)N(C)C1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 38
Group description: Subjects were dosed with approximately 1.0 mg/kg, using methohexital as anesthetic prior to electroconvulsive therapy.
Eligibility criteria:
Inclusion criteria:

Diagnosis of depression, either unipolar or bipolar
Subjects receiving ECT at the Mayo Clinic

Exclusion criteria:

Subjects not giving their own consent to ECT
Subjects with schizophrenia, schizoaffective disorder, or dementia
Subjects diagnosed with a major neurological disorder such as epilepsy, Parkinson disease, multiple sclerosis, or a neurodegenerative dementia.
Intervention: Bromfenac Sodium
Trial phase: Phase 3
SMILES: Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 212
Group description: Bromfenac ophthalmic solution 0.07% one drop into study eye, once daily (QD) starting the day before cataract surgery and continued for 14 days post surgery for a total of 16 days.

Bromfenac Ophthalmic Solution: Sterile ophthalmic solution
Eligibility criteria:
Inclusion Criteria:

Male or female at least 18 years of age who are scheduled for unilateral cataract surgery

Exclusion Criteria:

Have known hypersensitivity to bromfenac or to any component of the investigational product
Intervention: Growth hormone
Trial phase: Not Applicable
SMILES: CC(C)CC1NC(=O)C(CCC(=O)O)NC(=O)C2CSSCC3NC(=O)C(C)NC(=O)C4CCCN4C(=O)C(CC(N)=O)NC(=O)C(CSSCC(NC(=O)C(Cc4ccc(O)cc4)NC(=O)C(CC(N)=O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(N)CC(N)=O)C(=O)N2)NC(=O)C(CSSC(C(=O)NC(Cc2ccc(O)cc2)C(=O)O)NC(=O)CNC(=O)C(C(C)O)NC3=O)NC1=O
Sex: Female
Age groups: Child
Healthy volunteers: No
Participants at risk: 17
Group description: Subjects in the somatotropin (growth hormone, GH) arm will receive GH injections from 12-24 months of life.

somatotropin: Subjects will receive 5 mg somatotropin (growth hormone) pens with cartridges. Subcutaneous injections are to be given every evening around bedtime. Dosing regimen: 50 mcg/kg/day to be adjusted at 4 month intervals to the closest 0.1 mg. Subjects will be given 12 months of treatment (from 12 to 24 months of life). Subjects will visit their pediatrician or pediatric endocrinologist at 4 and 8 months of life.
Eligibility criteria:
Inclusion Criteria:

Diagnosis of Turner syndrome
Less than the 50th percentile for length for the general female population

Exclusion Criteria:

Prior Growth Hormone (GH) therapy
Diabetes
Allergy to metacresol (a preservative in the GH liquid that is injected)
Contraindications for Magnetic Resonance Imaging (MRI) (such as metal in the body)
Part of a Y chromosome in child's karyotype
Parent/guardian is not willing for child to be randomized to be in the treatment group (receives Growth Hormone injections for one year) or the control group (receives no Growth Hormone during the study)
Parent/guardian is not willing for child to have some of her developmental testing digitally recorded for scoring
Intervention: Citalopram
Trial phase: Phase 2
ATC code: N06AB04 | N06AB10
SMILES: CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 16
Group description: Escitalopram was started at 10 mg per day and increased to 20 mg if deemed clinically necessary, at week 4. No medication changes were made after week.
Eligibility criteria:
Inclusion Criteria:

Closed head injury
Fulfill Diagnostic and Statistical Manual Diploma in Social Medicine (DSM) IV criteria "Major Depressive Disorder"
18 years of age or older
Able to provide informed consent
Stable medical history

Exclusion Criteria:

History of Stroke, Encephalitis, Seizures, or any other pre-TBI neurological diseases
History of mental retardation
Alcohol or Substance dependence in the last 1 year
Inability to undergo MRI scan
Pregnancy
Current use of any psychotropic medications including any antidepressants, antipsychotics, anxiolytics, or sedative hypnotics
Poor response to escitalopram in the past
Acutely suicidal or requiring inpatient psychiatric hospitalization, as determined by the study psychiatrist
Good medication response to another antidepressant in the past
Intervention: Methylnaltrexone
Trial phase: Not Applicable
ATC code: A06AH01
SMILES: C[N@+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: Participants received single dose of MNTX 0.15 mg/kg SC initially. Subsequent dosing was adjusted upward (to a maximum of 0.3 mg/kg) to achieve a desired clinical response or decreased to improve tolerability. Median treatment duration was 25 days.
Eligibility criteria:
Inclusion Criteria:

Advanced medical illness (that is; terminal illness, such as incurable cancer or end stage aqcuired immunodeficiency syndrome [AIDS]) with a life expectancy of one to six months.
On an opioid regimen for the control of pain/discomfort for at least seven days.
Has opioid-induced constipation.
Stable vital signs and systolic blood pressure greater than or equal to (>=) 85 millimeters of mercury (mmHg), and diastolic blood pressure >=45 mmHg (Supine or sitting).
Females of childbearing potential must have a negative pregnancy test (serum or urine).
On a laxative regimen (for example, stool softener and SENNA or equivalent) for at least 3 days prior to treatment. Participants who have discontinued laxatives due to intolerability or lack of efficacy are also eligible.

Exclusion Criteria:

Participants with known hypersensitivity to methylnaltrexone, naltrexone or naloxone.
Participants who received any investigational new drug (experimental) except for methylnaltrexone in the previous 30 days.
Participants who are constipated with a disease process suggestive of gastrointestinal obstruction, impaction or diagnosed with a current abdominal pathologic process which may represent a non-opioid cause of bowel dysfunction.
Participants who are constipated and have active, clinically significant diverticulitis.
Participants with a surgically acute abdomen.
Participants being treated with opioids for diarrhea, dyspnea, cough, pulmonary edema, or congestive heart failure.
Individuals with a known drug addiction.
Females who are pregnant or nursing.
Intervention: SODIUM CHLORIDE
Trial phase: Phase 4
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 100
Group description: Saline Solution 2 ml at induction, 1-2 ml boluses as needed

Fentanyl: Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed
Eligibility criteria:
Inclusion Criteria

Patients scheduled to undergo outpatient arthroscopic surgery procedures
Willingness and ability to sign an informed consent document
No allergies to anesthetic or analgesic medications
18 - 80 years of age
American Society of Anesthesiologists (ASA) Class I - III adults of either sex
Women of childbearing potential must be currently practicing an acceptable form of birth control, and have a negative urine pregnancy test

Exclusion Criteria

Patients with known allergy, hypersensitivity or contraindications to anesthetic or analgesic medications
Patients with clinically-significant medical conditions, such as brain, heart, kidney, endocrine, or liver diseases, peptic ulcer disease or bleeding disorders
Pregnant or lactating women
Subjects with a history of alcohol or drug abuse within the past 3 months
Any other conditions or use of any medication which may interfere with the conduct of the study (e.g., asthmatic patients history of asthma, chronic cough, or upper respiratory tract infection during the previous 2 wk or recent treatment with angiotensin-converting enzyme inhibitors, bronchodilators, or steroids.
Intervention: Ketamine
Trial phase: Phase 1
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Cohort of three participants treated at 0.5 mg/kg/dose oral ketamine.
Eligibility criteria:
Inclusion Criteria:

Subject, parent, or guardian willing and able to give informed consent
NRS for pain >4
Chronic pain, which has been present for >3 months, or persisting longer than is normal for the underlying diagnosis
Chronic pain related to diagnoses including but not limited to: cancer, rheumatologic disease, sickle cell anemia, cystic fibrosis, pancreatitis, and neuromuscular disease (e.g. Duchenne muscular dystrophy)
Able to tolerate and cooperate with neurocognitive assessment
Age 8-22 years old

Exclusion Criteria:

If they are known or suspected to have drug dependence or addiction
History of psychiatric disorder such as depression, schizophrenia, or bipolar disorder
History of hypertension
Unable to cooperate with neurocognitive assessment
Chronic pain related to chronic abdominal pain syndrome
Known liver disease or elevation of AST or ALT greater than 3 times the upper limit of normal.
Previous intolerance or allergic reaction to ketamine
Pregnancy
Use of CYP3A4 inhibitors or inducers within the 2 week period prior the study drug administration or within 5 half-lives of the respective medication, whichever is longer, until study conclusion.
Consumption of grapefruit or grapefruit products from at least 2 weeks prior to study drug administration until study conclusion.
Intervention: Ketamine
Trial phase: Phase 1
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Cohort of three participants treated at 1 mg/kg/dose oral ketamine.
Eligibility criteria:
Inclusion Criteria:

Subject, parent, or guardian willing and able to give informed consent
NRS for pain >4
Chronic pain, which has been present for >3 months, or persisting longer than is normal for the underlying diagnosis
Chronic pain related to diagnoses including but not limited to: cancer, rheumatologic disease, sickle cell anemia, cystic fibrosis, pancreatitis, and neuromuscular disease (e.g. Duchenne muscular dystrophy)
Able to tolerate and cooperate with neurocognitive assessment
Age 8-22 years old

Exclusion Criteria:

If they are known or suspected to have drug dependence or addiction
History of psychiatric disorder such as depression, schizophrenia, or bipolar disorder
History of hypertension
Unable to cooperate with neurocognitive assessment
Chronic pain related to chronic abdominal pain syndrome
Known liver disease or elevation of AST or ALT greater than 3 times the upper limit of normal.
Previous intolerance or allergic reaction to ketamine
Pregnancy
Use of CYP3A4 inhibitors or inducers within the 2 week period prior the study drug administration or within 5 half-lives of the respective medication, whichever is longer, until study conclusion.
Consumption of grapefruit or grapefruit products from at least 2 weeks prior to study drug administration until study conclusion.
Intervention: SODIUM CHLORIDE
Trial phase: Phase 4
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 66
Group description: We administrate the saline single bolus (5ml, intravenously) 30 min before the commencement of ischemia.
Eligibility criteria:
Inclusion Criteria:

Adults above age of 20
Undergoing Thoracic Aorta Surgery with Hypothermic Cardiac Arrest

Exclusion Criteria:

pregnancy or lactation
cerebrovascular thrombosis 3. past history of pulmonary embolism or thrombosis
past history of thoracic aortic surgery
malignancy 5. preoperative acute kidney injury
chronic renal replacement therapy
allergy or hypersensitivity to erythropoetin
history of erythropoetin treatment
death during or one day after surgery
no consent
reoperation within seven days of the first surgery
Intervention: Prednisolone
Trial phase: Phase 2
ATC code: A01AC04 | A01AC54 | A07EA01 | C05AA04 | D07AA03 | D07BA01 | D07CA03 | D07XA02 | H02AB06 | R01AD02 | R01AD52 | S01BA04 | S01BB02 | S01CA02 | S01CB02 | S02BA03 | S02CA01 | S03BA02 | S03CA02 | V03AB05
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 32
Group description: Prednisolone 2.7 mg daily
Eligibility criteria:
Inclusion Criteria:

Meet the ACR / EULAR criteria for classification of RA
Have moderate to severe RA, defined as involving a minimum (≥6 total swollen and ≥6 total tender) of the 28 joints assessed
Have screening CRP levels of at least 0.6 mg/dl and a DAS28-CRP score ≥4.5
Have been on a stable dose of conventional DMARD therapy for at least 90 days without dosage adjustment or modification and should be able to maintain the same dose of conventional DMARD therapy during study participation (with or without glucocorticoid therapy

Exclusion Criteria:

Treatment-refractory patients are excluded
Has active cardiovascular disease, unless well controlled by appropriate treatment for a minimum of 3 months prior to screening
Is taking aspirin for reasons other than for cardiovascular prophylaxis or their total daily dose is greater than 325 mg
Is currently taking steroids at a daily prednisone dose, or the equivalent, of >10 mg
Intraarticular, intramuscular, or intravenous glucocorticoids must not have been given at least 6 weeks prior to entering the study
The need to continue the use of one or multiple NSAID's at the same time, or the use of acetaminophen on a chronic basis
All opiate use is prohibited
Use of any other medications or herbs used for the treatment of pain is prohibited
Patients with a history of or currently active tuberculosis as per specific country guidelines are excluded
Has uncontrolled diabetes mellitus as defined by a serum glucose >126 mg/dl
Knowingly has HIV infection or hepatitis
Has undergone administration of any investigational drug within 30 days of study initiation
All biologic agents are excluded for 90 days prior to Screening and throughout the study.
Has undergone administration of rituximab or any B-cell depleting investigational drugs within 6 months of study initiation
Has had a history of alcohol or drug abuse within the past 2 years
Has a history of hypersensitivity to glucocorticoids and/or dipyridamole
Intervention: Dipyridamole
Trial phase: Phase 2
ATC code: B01AC07
SMILES: OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 41
Group description: dipyridamole 360 mg once daily
Eligibility criteria:
Inclusion Criteria:

Meet the ACR / EULAR criteria for classification of RA
Have moderate to severe RA, defined as involving a minimum (≥6 total swollen and ≥6 total tender) of the 28 joints assessed
Have screening CRP levels of at least 0.6 mg/dl and a DAS28-CRP score ≥4.5
Have been on a stable dose of conventional DMARD therapy for at least 90 days without dosage adjustment or modification and should be able to maintain the same dose of conventional DMARD therapy during study participation (with or without glucocorticoid therapy

Exclusion Criteria:

Treatment-refractory patients are excluded
Has active cardiovascular disease, unless well controlled by appropriate treatment for a minimum of 3 months prior to screening
Is taking aspirin for reasons other than for cardiovascular prophylaxis or their total daily dose is greater than 325 mg
Is currently taking steroids at a daily prednisone dose, or the equivalent, of >10 mg
Intraarticular, intramuscular, or intravenous glucocorticoids must not have been given at least 6 weeks prior to entering the study
The need to continue the use of one or multiple NSAID's at the same time, or the use of acetaminophen on a chronic basis
All opiate use is prohibited
Use of any other medications or herbs used for the treatment of pain is prohibited
Patients with a history of or currently active tuberculosis as per specific country guidelines are excluded
Has uncontrolled diabetes mellitus as defined by a serum glucose >126 mg/dl
Knowingly has HIV infection or hepatitis
Has undergone administration of any investigational drug within 30 days of study initiation
All biologic agents are excluded for 90 days prior to Screening and throughout the study.
Has undergone administration of rituximab or any B-cell depleting investigational drugs within 6 months of study initiation
Has had a history of alcohol or drug abuse within the past 2 years
Has a history of hypersensitivity to glucocorticoids and/or dipyridamole